Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene
Masafumi Saiki, Fumiyoshi Ohyanagi, Ryo Ariyasu et al. · Japanese Journal of Clinical Oncology · 2017
Inflammatory myofibroblastic tumor (IMT) is a neoplasm characterized by the proliferaton of myofibroblasts with the infiltration of inflammatory cells. There is no standard treatment for patients with recurrent or metastatic IMT. We describe here a patient with hyper-progressive IMT with an anaplastic lymphoma kinase (ALK) fusion gene that dramatically responded to alectinib without adverse events. His dramatic and enduring response supports the observation that alectinib may be considered a good treatment option for rare aggressive ALK-positive tumors.
Cited by 29 works. doi:10.1093/jjco/hyx133
Authors
- Masafumi Saiki
- Fumiyoshi Ohyanagi
- Ryo Ariyasu
- Junji Koyama
- Tomoaki Sonoda
- Shingo Nishikawa
- Satoru Kitazono
- Noriko Yanagitani
- Atsushi Horiike
- Hironori Ninomiya
- Yuichi Ishikawa
- Makoto Nishio
References
- WHO classification of tumours of soft tissue and bone
- Extrapulmonary Inflammatory Myofibroblastic Tumor (Inflammatory Pseudotumor) A Clinicopathologic and Immunohistochemical Study of 84 Cases
- Inflammatory Myofibroblastic Tumor
- Crizotinib in ALK -Rearranged Inflammatory Myofibroblastic Tumor
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
- Inflammatory pseudotumors of the lung
- Inflammatory Pseudotumors, Lung
- Inflammatory Pseudotumor of the Lung in Adults
- Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP